A new perspective for advanced positron emission tomography–based molecular imaging in neurodegenerative proteinopathies

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

A new perspective for advanced positron emission tomography–based molecular imaging in neurodegenerative proteinopathies. / IMBI Project.

In: Alzheimer's and Dementia, Vol. 15, No. 8, 01.01.2019, p. 1081-1103.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

IMBI Project 2019, 'A new perspective for advanced positron emission tomography–based molecular imaging in neurodegenerative proteinopathies', Alzheimer's and Dementia, vol. 15, no. 8, pp. 1081-1103. https://doi.org/10.1016/j.jalz.2019.02.004

APA

IMBI Project (2019). A new perspective for advanced positron emission tomography–based molecular imaging in neurodegenerative proteinopathies. Alzheimer's and Dementia, 15(8), 1081-1103. https://doi.org/10.1016/j.jalz.2019.02.004

Vancouver

IMBI Project. A new perspective for advanced positron emission tomography–based molecular imaging in neurodegenerative proteinopathies. Alzheimer's and Dementia. 2019 Jan 1;15(8):1081-1103. https://doi.org/10.1016/j.jalz.2019.02.004

Author

IMBI Project. / A new perspective for advanced positron emission tomography–based molecular imaging in neurodegenerative proteinopathies. In: Alzheimer's and Dementia. 2019 ; Vol. 15, No. 8. pp. 1081-1103.

Bibtex

@article{837b6307f84d4ed89d8d7c265e4d1556,
title = "A new perspective for advanced positron emission tomography–based molecular imaging in neurodegenerative proteinopathies",
abstract = "Recent studies in neurodegenerative conditions have increasingly highlighted that the same neuropathology can trigger different clinical phenotypes or, vice-versa, that similar phenotypes can be triggered by different neuropathologies. This evidence has called for the adoption of a pathology spectrum-based approach to study neurodegenerative proteinopathies. These conditions share brain deposition of abnormal protein aggregates, leading to aberrant biochemical, metabolic, functional, and structural changes. Positron emission tomography (PET) is a well-recognized and unique tool for the in vivo assessment of brain neuropathology, and novel PET techniques are emerging for the study of specific protein species. Today, key applications of PET range from early research and clinical diagnostic tools to their use in clinical trials for both participants screening and outcome evaluation. This position article critically reviews the role of distinct PET molecular tracers for different neurodegenerative proteinopathies, highlighting their strengths, weaknesses, and opportunities, with special emphasis on methodological challenges and future applications.",
keywords = "Amyloid, Neuroinflammation, PET molecular imaging, Protheinopathies, Radiotracers, Tau",
author = "Daniela Perani and Leonardo Iaccarino and Lammertsma, {Adriaan A.} and Windhorst, {Albert D.} and Paul Edison and Ronald Boellaard and Oskar Hansson and Agneta Nordberg and Jacobs, {Andreas H.} and Michel Bottlaender and David Brooks and Carroll, {Michael A.} and Sylvie Chalon and Anthony Gee and Alexander Gerhard and Christer Halldin and Karl Herholz and Herth, {Matthias M.} and Rainer Hinz and Knudsen, {Gitte M.} and Bertrand Kuhnast and Francisco L{\'o}pez-Pic{\'o}n and Moresco, {Rosa Maria} and Sabina Pappata and Rinne, {Juha O.} and Elena Rodriguez-Vieitez and Santiago-Ribeiro, {Marie Joao} and Turkheimer, {Federico E.} and {Van Laere}, Koen and Andrea Varrone and Johnny Vercouillie and Alexandra Winkeler and {IMBI Project}",
year = "2019",
month = jan,
day = "1",
doi = "10.1016/j.jalz.2019.02.004",
language = "English",
volume = "15",
pages = "1081--1103",
journal = "Alzheimer's & Dementia",
issn = "1552-5260",
publisher = "Elsevier",
number = "8",

}

RIS

TY - JOUR

T1 - A new perspective for advanced positron emission tomography–based molecular imaging in neurodegenerative proteinopathies

AU - Perani, Daniela

AU - Iaccarino, Leonardo

AU - Lammertsma, Adriaan A.

AU - Windhorst, Albert D.

AU - Edison, Paul

AU - Boellaard, Ronald

AU - Hansson, Oskar

AU - Nordberg, Agneta

AU - Jacobs, Andreas H.

AU - Bottlaender, Michel

AU - Brooks, David

AU - Carroll, Michael A.

AU - Chalon, Sylvie

AU - Gee, Anthony

AU - Gerhard, Alexander

AU - Halldin, Christer

AU - Herholz, Karl

AU - Herth, Matthias M.

AU - Hinz, Rainer

AU - Knudsen, Gitte M.

AU - Kuhnast, Bertrand

AU - López-Picón, Francisco

AU - Moresco, Rosa Maria

AU - Pappata, Sabina

AU - Rinne, Juha O.

AU - Rodriguez-Vieitez, Elena

AU - Santiago-Ribeiro, Marie Joao

AU - Turkheimer, Federico E.

AU - Van Laere, Koen

AU - Varrone, Andrea

AU - Vercouillie, Johnny

AU - Winkeler, Alexandra

AU - IMBI Project

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Recent studies in neurodegenerative conditions have increasingly highlighted that the same neuropathology can trigger different clinical phenotypes or, vice-versa, that similar phenotypes can be triggered by different neuropathologies. This evidence has called for the adoption of a pathology spectrum-based approach to study neurodegenerative proteinopathies. These conditions share brain deposition of abnormal protein aggregates, leading to aberrant biochemical, metabolic, functional, and structural changes. Positron emission tomography (PET) is a well-recognized and unique tool for the in vivo assessment of brain neuropathology, and novel PET techniques are emerging for the study of specific protein species. Today, key applications of PET range from early research and clinical diagnostic tools to their use in clinical trials for both participants screening and outcome evaluation. This position article critically reviews the role of distinct PET molecular tracers for different neurodegenerative proteinopathies, highlighting their strengths, weaknesses, and opportunities, with special emphasis on methodological challenges and future applications.

AB - Recent studies in neurodegenerative conditions have increasingly highlighted that the same neuropathology can trigger different clinical phenotypes or, vice-versa, that similar phenotypes can be triggered by different neuropathologies. This evidence has called for the adoption of a pathology spectrum-based approach to study neurodegenerative proteinopathies. These conditions share brain deposition of abnormal protein aggregates, leading to aberrant biochemical, metabolic, functional, and structural changes. Positron emission tomography (PET) is a well-recognized and unique tool for the in vivo assessment of brain neuropathology, and novel PET techniques are emerging for the study of specific protein species. Today, key applications of PET range from early research and clinical diagnostic tools to their use in clinical trials for both participants screening and outcome evaluation. This position article critically reviews the role of distinct PET molecular tracers for different neurodegenerative proteinopathies, highlighting their strengths, weaknesses, and opportunities, with special emphasis on methodological challenges and future applications.

KW - Amyloid

KW - Neuroinflammation

KW - PET molecular imaging

KW - Protheinopathies

KW - Radiotracers

KW - Tau

U2 - 10.1016/j.jalz.2019.02.004

DO - 10.1016/j.jalz.2019.02.004

M3 - Journal article

C2 - 31230910

AN - SCOPUS:85067487439

VL - 15

SP - 1081

EP - 1103

JO - Alzheimer's & Dementia

JF - Alzheimer's & Dementia

SN - 1552-5260

IS - 8

ER -

ID: 226917939